Bank of Nova Scotia Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Bank of Nova Scotia lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.7% in the 1st quarter, Holdings Channel.com reports. The fund owned 97,520 shares of the biopharmaceutical company’s stock after selling 22,491 shares during the quarter. Bank of Nova Scotia’s holdings in Regeneron Pharmaceuticals were worth $75,348,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Gibbs Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals by 326.2% during the 1st quarter. Gibbs Wealth Management now owns 2,306 shares of the biopharmaceutical company’s stock valued at $1,782,000 after acquiring an additional 1,765 shares in the last quarter. Sei Investments Co. increased its holdings in Regeneron Pharmaceuticals by 32.5% in the 1st quarter. Sei Investments Co. now owns 75,000 shares of the biopharmaceutical company’s stock valued at $57,948,000 after purchasing an additional 18,403 shares in the last quarter. Forefront Analytics LLC increased its holdings in Regeneron Pharmaceuticals by 7.7% in the 1st quarter. Forefront Analytics LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $355,000 after purchasing an additional 33 shares in the last quarter. Militia Capital Management LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $2,318,000. Finally, Arvest Bank Trust Division purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $377,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on REGN. HSBC decreased their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Cantor Fitzgerald decreased their price target on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating for the company in a report on Monday, July 6th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $787.88.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Several articles say Regeneron is expected to beat second-quarter earnings estimates, which could reinforce confidence ahead of the company’s upcoming report. Analysts cited stronger-than-expected fundamentals as a reason for optimism. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim reportedly raised its price target on Regeneron to $1,000, a sign that at least one Wall Street firm remains very constructive on the company’s long-term prospects. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: More pre-earnings coverage suggests analysts expect earnings to decline year over year, so the upcoming report will need to show strong execution to keep sentiment positive. Here’s What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report
• Negative Sentiment: A wave of class-action lawsuit alerts and deadline reminders is weighing on sentiment, with allegations tied to disclosures around a Phase III Fianlimab-Libtayo melanoma trial and claims that risks were understated. SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Negative Sentiment: Multiple law firms are urging investors to join securities fraud litigation, highlighting the earlier sharp share-price drop after the failed Phase 3 trial announcement and keeping legal overhang front and center. REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit – Investors With Losses May Contact Levi & Korsinsky

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $651.91 on Friday. The firm has a 50-day moving average of $636.62 and a two-hundred day moving average of $714.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock has a market cap of $68.92 billion, a P/E ratio of 15.88, a PEG ratio of 1.44 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the previous year, the company earned $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.